Prevalence and Predictors of Antioxidant Supplement Use During Breast Cancer Treatment The Long Island Breast Cancer Study Project
Prevalence and Predictors of Antioxidant Supplement Use During Breast Cancer Treatment The Long Island Breast Cancer Study Project
复制标题
DOI：
10.1002/cncr.24378
复制
发表时间：
2009-07-15
期刊：
影响因子：
6.2
通讯作者：
Jacobson, Judith S.
中科院分区：
文献类型：
--
作者：
Greenlee, Heather;Gammon, Marilie D.;Jacobson, Judith S.
背景。尽管许多患者在乳腺癌治疗期间服用抗氧化剂膳食补充剂，但这种补充剂的益处尚未得到证实。本报告的作者分析了参与长岛乳腺癌研究项目的女性在乳腺癌 (BC) 治疗期间使用抗氧化剂补充剂的流行情况以及与抗氧化剂补充剂相关的因素。方法。 2002 年至 2004 年期间，曾参加过 1996 年至 1997 年病例对照研究的 BC 女性被邀请参加后续访谈。抗氧化剂补充剂的使用被定义为任何自我报告的维生素C、维生素E、β-胡萝卜素或单独补充剂或多种维生素中的硒的摄入量。结果。与未做出回应的女性相比，后续访谈的参与者更年轻，主要是白人，社会经济地位更高。在完成后续访谈的 764 名参与者中，663 名 (86.8%) 报告接受了 BC 的辅助治疗。在这 663 名女性中，401 名 (60.5%) 报告在辅助治疗期间使用了抗氧化剂：310 名女性中的 120 名 (38.7%) 在化疗期间使用了抗氧化剂，464 名女性中的 196 名 (42.2%) 在放疗期间使用了抗氧化剂，462 名女性中的 286 名 (61.9%) 在他莫昔芬治疗期间使用了抗氧化剂。在 401 名抗氧化剂使用者中，278 名女性 (69.3%) 使用高剂量（高于 Centrum 复合维生素中所含的剂量）。治疗期间使用高抗氧化剂补充剂相关的因素包括诊断时较高的水果和蔬菜摄入量（相对风险 [RR]，1.71；95% 置信区间 [CI]，1.13-2.59）、使用他莫昔芬（RR，3.66；95% CI，2.32-5.78）、曾经使用草药产品（RR，3.49；95% CI， 2.26-5.38），并且一直从事身心练习（RR，1.72；95% CI，1.13-2.64）。结论。鉴于在 BC 治疗期间普遍使用抗氧化剂补充剂（通常是高剂量）并与其他补充疗法结合使用，未来的研究应该解决抗氧化剂补充剂对 BC 结局的影响。癌症 2009；115：3271-82。 (C) 2009 年美国癌症协会。
BACKGROUND. Although many patients take antioxidant dietary supplements during breast cancer treatment, the benefits of such supplementation are unproven. The authors of this report analyzed the prevalence of and factors associated with antioxidant supplement use during breast cancer (BC) treatment among women who participated in the Long Island Breast Cancer Study Project. METHODS. From 2002 through 2004, women with BC who had participated a case-control study from 1996 to 1997 were invited to participate in a follow-up interview. Antioxidant supplement use was defined as any self-reported intake of supplemental vitamin C, vitamin E, beta-carotene, or selenium in individual supplements or multivitamins. RESULTS. Follow-up interview participants were younger, more predominantly white, and of higher socioeconomic status than women who did not respond. Among 764 participants who completed the follow-up interview, 663 (86.8%) reported receiving adjuvant treatment for their BC. Of those 663 women, 401 (60.5%) reported using antioxidants during adjuvant treatment: One hundred twenty of 310 women (38.7%) used antioxidants during chemotherapy, 196 of 464 women (42.2%) used them during radiation, and 286 of 462 women (61.9%) used them during tamoxifen therapy. Of 401 antioxidant users, 278 women (69.3%) used high doses (doses higher than those contained in a Centrum multivitamin). The factors that were associated with high antioxidant supplement use during treatment were higher fruit and vegetable intake at diagnosis (relative risk [RR], 1.71; 95% confidence interval [CI], 1.13-2.59), tamoxifen use (RR, 3.66; 95% CI, 2.32-5.78), ever using herbal products (RR, 3.49; 95% CI, 2.26-5.38), and ever engaging in mind-body practices (RR, 1.72; 95% CI, 1.13-2.64). CONCLUSIONS. Given the common use of antioxidant supplements during BC treatment, often at high doses and in conjunction with other complementary therapies, future research should address the effects of antioxidant supplementation on BC outcomes. Cancer 2009;115:3271-82. (C) 2009 American Cancer Society.